Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 10, 2025 (12 months ago)

Gabapentin Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Gabapentin Capsules, USP, 100 mg, 10 Capsules (10 x 1 blister pack), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61 (Blister pack), NDC 55154-3363-0 (Outer Bag).

Affected NDCs 0904-6665-61 55154-3363-00

Compare with the code on your package — it is the most precise check available.

Drug: Gabapentin Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product codes this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Gabapentin
NDC 00904-6665
100 mg/1 Capsule
Oral
Major Pharmaceuticals Rx
Gabapentin
NDC 55154-3363
100 mg/1 Capsule
Oral
Cardinal Health 107, LLC Rx
Recalling firm
The Harvard Drug Group LLC
NDC code
0904-6665-61
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0031-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Gabapentin recalls

See all
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025

Other recalls by The Harvard Drug Group LLC

All 2025 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026